Climateer Investing
In war, everything not censored is a lie.
Wednesday, April 1, 2020
Climateer Line of the Day: Everyone's a Virologist Edition
Evercore analyst on the study in the
NYT story
below:
"This trial design reads pretty decent,” he wrote Monday.
“However, the way in which results were reported
(and omitted) makes it hard to draw definitive conclusions.”
—Evercore ISI's Umer Raffat as quoted in Barron's
"
Another Hydroxychloroquine Trial Still Leaves Questions on Its Use Against Covid-19
"
Newer Post
Older Post
Home